🇺🇸 Trametinib tablet in United States
43 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 23 April 2025 – 23 April 2026
- Total reports: 43
Most-reported reactions
- Pyrexia — 12 reports (27.91%)
- Chills — 7 reports (16.28%)
- Squamous Cell Carcinoma — 4 reports (9.3%)
- Alanine Aminotransferase Increased — 3 reports (6.98%)
- Aspartate Aminotransferase Increased — 3 reports (6.98%)
- Diarrhoea — 3 reports (6.98%)
- Nausea — 3 reports (6.98%)
- Squamous Cell Carcinoma Of Skin — 3 reports (6.98%)
- Vomiting — 3 reports (6.98%)
- Abdominal Pain — 2 reports (4.65%)
Other Oncology approved in United States
Frequently asked questions
Is Trametinib tablet approved in United States?
Trametinib tablet does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Trametinib tablet in United States?
West China Hospital is the originator. The local marketing authorisation holder may differ — check the official source linked above.